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BRIEF REPORT

Rotavirus vaccine response correlates with the infant gut microbiota composition
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W. Joost Wiersingab, Carlo Giaquintog, Carolina de Weerthh, and Willem M. de Vos d,e
a
Amsterdam Institute for Global Health and Development and Department of Global Health, Academic Medical Center, University of
Amsterdam, Amsterdam, The Netherlands; bCenter for Experimental and Molecular Medicine, Division of Infectious Diseases, Academic Medical
Center, University of Amsterdam, Amsterdam, The Netherlands; cDepartment of Pediatrics and Child Health, Aga Khan University, Karachi,
Pakistan; dLaboratory of Microbiology, Wageningen University, Wageningen, The Netherlands; eRPU Immunobiology, Department of
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Respiratory Diseases, Center for Disease Control and Prevention, Atlanta, Georgia, USA; gDepartment of Paediatrics, University of Padova,
Padova, Italy; hBehavioral Science Institute, Department of Developmental Psychology, Radboud University, Nijmegen, The Netherlands

ABSTRACT

ARTICLE HISTORY

Rotavirus (RV) is the leading cause of diarrhea-related death in children worldwide and ninety-ﬁve
percent of rotavirus deaths occur in Africa and Asia. Rotavirus vaccines (RVV) can dramatically
reduce RV deaths, but have low efﬁcacy in low-income settings where they are most needed. The
intestinal microbiome may contribute to this decreased RVV efﬁcacy. This pilot study hypothesizes
that infants’ intestinal microbiota composition correlates with RVV immune responses and that RVV
responders have different gut microbiota as compared to non-responders.
We conducted a nested, matched case-control study comparing the pre-vaccination intestinal
microbiota composition between 10 6-week old Pakistani RVV-responders, 10 6-week old Pakistani
RVV non-responders, and 10 healthy Dutch infants.
RVV response was deﬁned as an
Immunoglobulin A of 20 IU/mL following RotarixTM (RV1) vaccination in an infant with a prevaccination IgA<20. Infants were matched in a 1:1 ratio using ranked variables: RV1 dosing
schedule (6/10/14; 6/10; or 10/14 weeks), RV season, delivery mode, delivery place, breastfeeding
practices, age and gender. Fecal microbiota analysis was performed using a highly reproducible
phylogenetic microarray.
RV1 response correlated with a higher relative abundance of bacteria belonging to Clostridium
cluster XI and Proteobacteria, including bacteria related to Serratia and Escherichia coli. Remarkably,
abundance of these Proteobacteria was also signiﬁcantly higher in Dutch infants when compared to
RV1-non-responders in Pakistan.
This small but carefully matched study showed the intestinal microbiota composition to correlate
with RV1 seroconversion in Pakistan infants, identifying signatures shared with healthy Dutch infants.
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Introduction
Rotavirus (RV) is one of the most important causes of
diarrhea-related death in children under the age of ﬁve
worldwide, particularly in Africa and Asia, where over
95% of RV deaths occur.1 Since their introduction, rotavirus vaccines (RVV) have signiﬁcantly reduced the
number of cases of serious rotavirus gastroenteritis in
developing country settings, however their effectiveness
is disappointingly low.2,3 In wealthy countries RVV
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have an efﬁcacy of as high as 85–98% against severe RVrelated gastroenteritis,4-7 however this efﬁcacy drops signiﬁcantly in low-income countries.8 Well-performed
randomized controlled studies in Africa and Asia have
shown a combined vaccine efﬁcacy ranging from 48 to
64% for the RotarixTM and RotaTeqTM vaccines and
53% for the human-bovine (116E) rotavirus vaccine in
India.9-12 RotarixTM is currently being introduced in
Pakistan’s Expanded Program on Immunization (EPI).
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Improving RVV efﬁcacy in low-income settings
could save hundreds of thousands of children’s lives.13
Several studies have demonstrated that the etiology of
RVV’s diminished immunogenicity is likely multi-factorial: due to interference from the ﬁrst dose of coadministered oral polio vaccine (OPV), host FUT2 and
FUT3 receptor status and HLA blood group antigen
type (HBGA), as well as RVV immune response suppression from maternally derived antibodies.14-17 Yet
these explanations fail to completely explain how RVV
seroconversion can be even lower than 40% in some
settings like an urban slum in Karachi, Pakistan.18,19
Given that the intestinal microbiome differs signiﬁcantly in different geographic populations,20 evidence is
emerging that differences in the intestinal microbiome
may help explain this gap in RVV immunogenicity.21,22
This study describes a pilot to explore whether the
infant intestinal microbiota may correlate with RVV
immunogenicity in a poor urban slum setting. We
hypothesized that if the composition of the intestinal
microbiota is inﬂuencing RVV response, then RVV responders should have a different intestinal microbiome
composition as compared to non-responders. To test
this, we conducted an exploratory, nested, case-control
pilot study in Karachi, Pakistan comparing the differences in pre-vaccination fecal microbiota composition
between infants with and without an anti-rotavirus
Immunoglobulin (Ig) A seroconversion to RV1.
A second hypothesis was that if there are biologically signiﬁcant differences in microbiome composition between vaccine responders and non-responders
within Pakistan, one would expect similar differences
in microbiome composition to exist between developing and developed country infants (with assumed high
RV1 seroconversion rate). Speciﬁcally, one would
assume a positive or negative gradient in microbiome
differences across populations – developed country,
then Pakistani responders then Pakistani non-responders. To test this hypothesis, we additionally compared the microbiome composition of Pakistani
infants to a cohort of healthy Dutch infants.

consent, and 1 died. Seventy-four children were screened
for their anti-RV IgA response, and 2 had evidence of
previous RV natural exposure and one child had no
post-vaccination IgA measurement available. Therefore,
71 children were eligible and enrolled in this study.
Sufﬁcient and good-quality DNA was obtained from
66 of the 71 fecal samples (93%) and these were further
characterized using phylogenetic microarray analysis.
Ten (15%) of the 66 infants had an IgA  20 IU/mL
and classiﬁed as RV1 responders and these infants
were then carefully matched based on six relevant variables to an equal number of RV1 non-responders (see
Table 1 for baseline characteristics). No signiﬁcant differences between the vaccine responders and non-responders were identiﬁed for any of the variables
including malnutrition indices.

Results

In a second analysis, we hypothesized that if microbial
differences identiﬁed between RV1 responders and
non-responders in Pakistan were actually inﬂuencing
vaccine response, then similar differences should exist
between vaccine non-responders in Pakistan and children in wealthier countries, with high levels of RVV
protection. First we compared all Pakistani infants to a

Study population

A total of 88 infants with pre-vaccination fecal samples
were available from the original clinical trials. Of these,
14 children were excluded: 11 children migrated out of
the catchment area, 2 children had guardians refuse

Microbiota composition

When evaluating the microbiome composition as a
whole, a signiﬁcantly higher ratio of Gram-negative to
Gram-positive bacteria was observed in vaccine responders as compared to non-responders (2.6-fold
higher, p D 0.03). Subsequently, when evaluating
microbiome composition at the phylum level, RV1
responders had signiﬁcantly higher levels of Firmicutes, in particular bacteria belonging to the abundant
Clostridium cluster XI (p 0.02, FDR 0.36), and Proteobacteria (p 0.04, FDR 0.36) than non-responders.
(Supplementary Table 1 and Figs. 1A-B, and 2).
When evaluated at the genus-like level, several bacteria differed between responders and non-responders.
The most notable difference observed was in the relative abundance of Gram-negative bacteria related to
Serratia and Escherichia coli, which were positively
associated with vaccine response and were approximately 2 and 4-fold reduced, respectively in the nonresponders (p 0.01, FDR 0.19 for Serratia and p 0.00,
FDR 0.05 for E. coli) (Supplementary Table 2,
Figs. 1C, and 2).
Pakistani infants compared to healthy dutch infants
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Table 1. Baseline characteristics RV1 Non-responders and Responders.

N
Gender
Male
Female
RV1 dosing
6/10 wks
10/14 wks
6/10/14 wks
Rotavirus Season
Yes
No
Location of delivery
Home
Healthcare
Mode of delivery
Vaginal
C-section
Feeding
Breastfeeding
BF C Formula
Formula
Malnutrition
(Z score<¡2)
Length-for-age
Weight-for-length
Weight-for-age

RV1 Non-responders

RV1 Responders

p-value

Dutch infants

p-values (NL-NR; NL-R)

10/66 (15%)

10/66 (15%)

NA
0.65

10

NA

6/10 (60%)
4/10 (40%)

5/10 (50%)
5/10 (40%)

6/10
4/10

1.0; 0.65

1/10 (10%)
1/10 (10%)
8/10 (80%)

2/10 (20%)
1/10 (10%)
7/10 (70%)

4/10 (40%)
6/10 (60%)

4/10 (40%)
6/10 (60%)

4/10 (40%)
6/10 (60%)

3/10 (30%)
7/10 (70%)

9/10 (90%)
1/10 (10%)

9/10 (90%)
1/10 (10%)

9/10 (90%)
1/10 (10%)
0/10 (0%)

9/10 (90%)
1/10 (10%)
0/10 (0%)

1/10 (10%)
1/10 (10%)
1/10 (10%)

1/10 (10%)
1/10 (10%)
1/10 (10%)

0.82
NA
1.000

NA

0.64
4/10
6/10

1.0; 0.64

10/10
0/10

0.29; 0.29

7/10
2/10
1/10

0.35; 0.35

0/10
0/10
0/10

0.22; 0.22

1.00
1.00

1.00

Note. Baseline characteristics of the infants enrolled in the nested study and differences between the Pakistani RV1 non-responders and responders as determined
by the Chi-square test. Baseline characteristics of the matched Dutch infants and differences between Dutch and Pakistani RV1 non-responders and responders,
respectively as determined by the Chi-square test. Abbreviations: RV1, Rotavirus vaccine; NL, Dutch infants.

set of 154 age-matched Dutch infants. Multivariate
analysis demonstrated a signiﬁcantly different overall
microbial composition between all Dutch infants and
Pakistani infants (p D 0.014), as expected by geography
(See Supplementary Fig. 1). We then made a response

index (Pakistani non-responders 1, responders 2, and
Dutch infants 3) to evaluate with a heat tree which bacteria correlated with hypothetical RVV response (Illustrated in Fig. 3). Subsequently, to limit potential
confounding, we matched 10 Dutch infants to 10

Figure 1. Distribution of the relative abundance of bacteria between Pakistani responders and non-responders. The relative abundance
(%) for all phyla (class for Firmicutes) (1A), signiﬁcantly different phyla (p < 0.05) (1B), and signiﬁcantly different bacteria at the genuslike level (FDR < 0.5) (1C) are illustrated. Bean plots compare Pakistani responders (1, orange) and non-responders (0, red). The horizontal black line is the median and the height of each bean plot illustrates the distribution of the values for abundance within each group.
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negative Proteobacteria had signiﬁcantly higher abundance in the Dutch infants (10-fold higher, FDR 9 £
10¡12), especially the Gammaproteobacteria (15-fold
higher, FDR 9 £ 10¡12) which includes bacteria such
as Serratia, E. coli, Klebsiella, and Enterobacter. (See
Supplementary Table 3). In addition, Dutch infants
had higher abundance of bacteria related to Staphylococci (4-fold increase, FDR 0.003) and the phylum Verrucomicrobiae
(5-fold
increase,
FDR.0002).
(Supplementary Table 3)

Discussion

Figure 2. Phylogenetic Heat Tree illustrates the differences in relative bacterial abundance between Pakistani non-responders and
responder infants. Colored blue are bacteria where a lower abundance associates with RVV response and colored red are bacterial
groups where a higher abundance correlates with RVV response.

Pakistani non-responder infants (Table 1). Bacterial
correlations with RVV response were very similar in
the matched and unmatched analyses. There were no
differences in diversity, richness, or evenness. Gram-

Figure 3. Phylogenetic Heat Tree illustrates the differences in relative bacterial abundance between all Pakistani non-responder,
Pakistani responder and Dutch infants when indexed by
response. Each group’s RVV response is indexed (Pakistani nonresponder 1, responder 2, and Dutch infants 3) and those bacteria
with signiﬁcant linear associations with index are colored.
Colored blue are bacteria where a lower abundance associates
with RVV response and colored red are bacterial groups where a
higher abundance correlates with RVV response.

In a cohort of 66 Pakistani infants, we observed only
10 to be seroconverted after RV1 vaccination, conﬁrming the low response often reported in lowincome countries. The pre-vaccination (6 weeks)
microbiota of the 10 responding infants was compared
with that of a carefully matched group of nonresponding Pakistani infants. We observed that the
RV1 response was positively correlated with increased
ratio of Gram-negative over Gram-positive bacteria,
notably reﬂected in an approximately 3-fold increased
abundance of the Proteobacteria related to Serratia
and E. coli. Interestingly, when the intestinal microbiota of matched Dutch infants with assumed high
RVV immunogenicity was compared with that of the
Pakistani RV1 non-responders, again signiﬁcantly
higher abundance of Proteobacteria was observed,
particularly Gammaproteobacteria which include bacteria related to Serratia and E. coli.
The results of this pilot study are best regarded as preliminary and hypothesis-generating for an under-developed research ﬁeld. Gram-negative bacteria, such as
Proteobacteria, can stimulate speciﬁc innate immune
responses, such as through their expression of ﬂagella or
toxigenic LPS. In this Pakistani infant population, Proteobacteria or their cell envelope components may therefore be acting as natural immune adjuvants. Murine
models have demonstrated that bacterial ﬂagella can cure
RV infections through an activation of the innate
immune system via TLR5 and NLRC4.23 Accordingly,
early exposure to Proteobacteria-expressing ﬂagella may
augment innate and subsequent adaptive immune
response to RV1. An additional hypothesis is that a
higher abundance of LPS derived from E. coli may also be
augmenting RV1 immune responses in responders –
accumulating data demonstrates that E.coli-derived LPS
has stronger immune-stimulatory capacity than LPS in
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the cell walls of other gram-negative organisms such as
those in the Bacteroidetes phylum.24,25 In a parallel study
correlating RV1 response with microbiome composition
in rural Ghana, we recently observed that a high abundance of Bacteroidetes in the fecal microbiome was negatively correlated with RV1 seroconversion.21 While
undeniably speculative, these two studies may complement one another – Proteobacteria and E. coli- derived
LPS might boost RV1 responses in some populations
whereas Bacteroidetes-derived, and potentially inhibitory, LPS might inhibit RV1 responses in others.
Alternatively, more abundant neonatal colonization
with Proteobacteria could have a role in educating the
innate immune system. While a high abundance of Proteobacteria is often correlated with an inﬂammatory gut
proﬁle,26 some evidence exists that E. coli may be particularly important in strengthening adaptive B cell immunity. Early colonization with E. coli was associated with
higher numbers of memory CD20C B cells at 4 and
18 months of age in a Swedish cohort.27
Finally, HBGA interactions may be modulating vaccine strain replication. Bacteria might be expressing
blood group antigens or glycans needed for RV replication, as has been demonstrated with norovirus.28 Given
the known association between HBGAs and microbiome
composition29 as well as HBGA and rotavirus immunogenicity,17,30 host genetics could be interacting with both
microbiome composition and viral replication.
This exploratory study has signiﬁcant limitations
restricting the generalizability of our ﬁndings despite
having high internal validity. The study is primarily
limited by power – the low vaccine response (15%)
among infants with an available fecal sample meant
that we were only able to evaluate 10 RV1 responders
in depth. Additionally, in the original dosing study, RV
IgA seroconversion was 36% to 39%, depending on
study arm, so the cohort of RV1 responder infants that
we were able to examine might be a skewed patient
population. Anti-RV IgA sero-conversion is also only a
correlate of vaccine protection, and clinical vaccine
efﬁcacy would require larger sample sizes and followup. Additionally, the infant microbiome is characterized by a low diversity and high inter-individual variability with large microbiome ﬂuctuations over time.20
We examined one time point directly prior to RV1 vaccination and our study is unable to account for variation over time. Nevertheless, we believe that the time
point directly prior to RV1 vaccination is the most
important window into the potential interaction
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between the rotavirus vaccine and the infant’s microbiome. A potential technical limitation is that the
HITChip phylogenetic microarray used in this study,
while validated in 1000s of subjects, has never been
tested in a developing country setting like Pakistan and
may not identify novel bacterial phylotypes. Since most
if not all intestinal genera are covered on this microarray, we expect that the cross-hybridization that occurs
would permit detection of the most abundant microbial populations, even if some phylotypes are not covered by the used probes. However, a similar problem
could also occur with sequencing techniques: sequences are mapped to a reference database. If the reference
database does not contain a phylotype because it is
novel the phylotype will be identiﬁed as the most similar, known phylotype, which is the same as what occurs
with HITChip cross-hybridization.
Conﬁrming these intriguing study results in other lowincome settings could help substantiate a role for the
intestinal microbiome in inﬂuencing rotavirus vaccine
efﬁcacy. Identiﬁcation of key bacterial phylotypes that
correlate with RVV response could also be the ﬁrst step
designing an intervention to improve RVV efﬁcacy. Such
a future intervention could have several theoretical forms
– modulation of the infant microbiota prior to vaccination with targeted antibiotics (not an ideal strategy in
infant populations), evidence-based probiotic or modulation via targeted bacteriophage therapy. Alternatively,
understanding of which bacteria elicit rotavirus vaccine
immunogenicity could support testing for novel adjuvantation of this oral vaccine. Finally, microbiota proﬁles
might be used to predict which infants are at risk for
RVV failure and in need of additional vaccine doses or
targeted education.

Methods
Study design and participants

All participating Pakistani infants were healthy, 4–6 weeks
of age at enrolment, with a birth-weight > 1500g (exact
gestational age unknown), and had been previously
enrolled in a phase IV, open-label randomized clinical
trial of RV1 immunogenicity (NCT01199874, clinicaltrials.gov) examining the effect of different RV1 dosing
schedules (6/10/14, 6/10 and 10/14 weeks) and withholding breastfeeding around the time of vaccine administration on RV1 immunogenicity.18,19
The trial was conducted in a peri-urban, lowincome slum along the seacoast in Karachi, Pakistan.
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Serum samples were collected prior to the ﬁrst dose of
vaccine and 28 days following the last dose of vaccine
(14 or 18 weeks depending on study arm) for antirotavirus IgA antibody measurements. Fecal samples
were collected directly (0–2 days) prior to and in the
week following vaccination for the ﬁrst 88 infants
enrolled in these trials, further fecal sample collection
was halted due to logistical issues.
Infants were included in the current study if guardians
had provided informed consent in the original phase IV
study and additionally consented to collection of a new
fecal sample collection (results not described here). Further inclusion criteria speciﬁed the availability of a baseline, pre-vaccination (0–2 days preceding vaccination)
fecal sample, and that there was no evidence of natural
RV infection prior to vaccination (a pre-vaccination IgA
20 IU/mL). IgA seroconversion to greater than 20 IU/
mL following vaccination was considered a surrogate
marker for RV1 protection against severe rotavirus gastroenteritis.31 Participating infants were grouped as either
RV1 responders (post-vaccination 14 and/or 18 week
anti-RV IgA antibody  20 IU/mL in infants with a prevaccination IgA < 20 IU/mL) or non-responders and
matched in a 1:1 ratio using the ranked variables: RV1
study arm (dose and breastfeeding arms), RV season in
Karachi (deﬁned as the date of the 28 days post-vaccination serum IgA falling between December 1st, 2011 and
February 1st, 2012), mode of delivery (vaginal or caesarean section), breastfeeding practices (exclusive breastfeeding, breastfeeding and formula, or formula only),
place of delivery (home or health care facility), age of fecal
sample collection (in weeks), and sex.
The nested trial was approved by the institutional
review board of Aga Khan University and was conducted
in accordance with good clinical practice guidelines.
In parallel, we anonymously compared the microbiota of healthy, full-term Dutch infants to our Pakistani RV1 non-responders and responders. These
healthy Dutch infants had not received RVV as RVV
is not included in the Dutch national vaccination program, but it was assumed that if they had, their RVV
seroconversion rate would be well over 90% based on
extensive efﬁcacy and effectiveness data for RVV in
Northern Europe.4,7 Only Dutch infants without colic,
co-morbidities, or maternal stress were eligible for
inclusion. The Pakistani infants were compared to an
age-matched only cohort of 154 infants and then compared to Dutch infants matched for gender, age at
fecal sample collection (4–5 weeks of age), place of

delivery, mode of delivery, breast-feeding practices,
and birth weight. Fecal samples from Dutch infants
were collected as part of a previously published study
(Bibo study) in which infants and mothers were followed from the third trimester to 5–6 years of age. All
infants’ fecal samples were stored, processed for DNA
extraction and further analysed in an identical protocol using the Human Intestinal Tract Chip (HITChip)
phylogenetic microarray (see below).32,33

Laboratory evaluations
IgA assay

Serum obtained 0–2 days prior to vaccination and
28 days post last RV1 dose was evaluated for anti-RV
IgA antibody. Anti-RV IgA antibody was measured in
serum using an enzyme-linked immunosorbent assay
(ELISA) described elsewhere, expressed as international units per milliliter (IU/mL).34
Fecal microbiota analysis

Fecal samples obtained 0–2 days prior to vaccination,
were kept at 0–4C after collection and were frozen to
¡80C within 24–48 hours of collection. Total DNA
was extracted from the fecal material by a repeated
bead beating procedure using a modiﬁed protocol for
the QiaAmp DNA MiniStool Kit (Qiagen, Hilden,
Germany) as previously described.35
Analysis of the microbiota composition was performed using the HITChip phylogenetic microarray,
which contains oligonucleotide probes for hypervariable
regions on the 16S rRNA gene.36 The HITChip is a comprehensive and highly reproducible phylogenetic
microarray that enables the parallel proﬁling and the
semi-quantitative analysis of over 1100 phylotypes representing all major intestinal phyla grouped in 130
genus-like groups described for the human intestinal
microbiota. Hybridization of extracted DNA from sample to the oligonucleotide probes on the HITChip yields a
signal intensity per probe and can thereby provide a
quantitative and qualitative phylogenetic proﬁling of the
microbiome composition. The HITChip has been used
in over a dozen studies and validated in analyses of over
1000 subjects.32,37
All samples were analyzed on two independent microarray experiments and the data only passed the quality
control if the inter-experiment Pearson correlation was
>0.97. The signal intensities were normalized using the
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fRPA method38 and summarized at different levels of
phylogenetic resolution: species, genus, and phylum,
except for the Firmicutes, which was further divided to
Clostridium clusters and Bacilli. This high-throughput
technique has been bench marked with ultra-deep
sequencing of 16S rRNA and next-generation parallel
sequencing of intestinal metagenomes.39,40
Statistical analysis

Cases were deﬁned as RV1 responders – infants with a
serum RV IgA < 20 IU/mL pre-vaccination and IgA 
20 IU/mL post-vaccination. Controls were deﬁned as
RV1 non-responders – infants with a serum RV
IgA < 20 IU/mL pre-vaccination and post-vaccination.
A Chi-square test was used to determine statistically
signiﬁcant differences in baseline characteristics between
RV1 responders (case) and non-responders (controls).
Comprehensive multivariate statistical analyses were
performed using Canoco 5.0 software for Windows.41
Principal coordinate (PCA) and redundancy analyses
(RDA) were used to evaluate differences in the overall
microbial composition between the study groups. The
130 genus-like bacterial groups targeted by the HITChip
were used as biological variables and environmental variables were the matching variables named above. Monte
Carlo permutation testing (MCPT) assessed the signiﬁcance of the effect of these variables in the data set.
The relative abundance of speciﬁc bacterial groups
in the fecal microbiota was determined at the genuslike level and at the phylum level (class for the Firmicutes). Generalized linear model with negative binomial distribution or generalized least squares model
were used to determine signiﬁcant differences in composition and p-values were corrected for false discovery rate (FDR) by the Benjamini-Hochberg method.
Graphical representations and modelling of the relative abundance and correlations with RVV response
were performed with the package mare42 within R,43
utilizing the packages nlme,44 MASS,45 bean plot,46
metacoder,47 and vegan.48
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